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Targeting EZH2-mediated 
methylation of H3K27 inhibits 
proliferation and migration of 
Synovial Sarcoma in vitro
Jacson K. Shen1,*, Gregory M. Cote2,*, Yan Gao1, Edwin Choy2, Henry J. Mankin1, 
Francis J. Hornicek1 & Zhenfeng Duan1
Synovial sarcoma is an aggressive soft tissue sarcoma genetically defined by the fusion oncogene SS18-
SSX. It is hypothesized that either SS18-SSX disrupts SWI/SNF complex inhibition of the polycomb 
complex 2 (PRC2) methyltransferase Enhancer of Zeste Homologue 2 (EZH2), or that SS18-SSX is 
able to directly recruit PRC2 to aberrantly silence target genes. This is of potential therapeutic value 
as several EZH2 small molecule inhibitors are entering early phase clinical trials. In this study, we 
first confirmed EZH2 expression in the 76% of human synovial sarcoma samples. We subsequently 
investigated EZH2 as a therapeutic target in synovial sarcoma in vitro. Knockdown of EZH2 by shRNA 
or siRNA resulted in inhibition of cell growth and migration across a series of synovial sarcoma cell 
lines. The EZH2 selective small-molecule inhibitor EPZ005687 similarly suppressed cell proliferation 
and migration. These data support the hypothesis that targeting EZH2 may be a promising therapeutic 
strategy in the treatment of synovial sarcoma; clinical trials are initiating enrollment currently.
Aberrant epigenetic changes are increasingly being recognized as important drivers of malignancy, including 
altered covalent histone amino tail modifications (e.g. acetylation, methylation, etc.), hyper- or hypo-DNA meth-
ylation, and dysregulation of the ATP-dependent chromatin remodeling enzymes that regulate these processes. 
ATP-dependent chromatin remodeling occurs via several intricate multiprotein complexes, which are thought 
to alter the nucleosome structure, thus regulating chromatin packaging and transcription (for a comprehensive 
review see Wilson et al.1 and Mermoud et al.2). There are five known ATP-dependent chromatin complexes of 
which the best characterized is SWI/SNF ([SWItch/Sucrose Non-Fermenting] several variants exist). SWI/SNF 
may function to either slide or remove the histone from the nucleosome and thereby alter the degree of chroma-
tin compaction (i.e. histone ejection from the nucleosome would open the chromatin and thus allow access of 
RNA polymerase complexes)3,4. In contrast, the polycomb group repressive complexes (PRC1 and PRC2) work in 
concert to modify histone tails to suppress transcription4,5. The PRC2 component Enhancer of Zeste Homolog 2 
(EZH2) is a potent histone methyltransferase that targets histone 3 lysine 27 (H3K27)6,7. Current models suggest 
antagonistic functions of SWI/SNF (activating transcription) and PRC2/EZH2 (silencing transcription) to fine 
tune levels of gene expression6,8,9.
Emerging data support SWI/SNF as an epigenetic tumor suppressor and EZH2 as an oncogene. Human tumor 
sequencing studies have identified multiple alterations in SWI/SNF across a range of malignancies10 and acti-
vating EZH2 mutations in lymphoma (and over-expression in other tumors)7,11–14, and in some these have been 
correlated with worse clinical outcomes15. Some examples of the SWI/SNF-PRC2/EZH2 oncogenesis hypothe-
sis include malignant rhabdoid tumors (MRT) in which the SWI/SNF subunit INI1 (a.k.a. hSNF5, SMARCB1, 
BAF47) is inactivated, and in lymphomas with EZH2 activating mutations. In preclinical models of MRT, rescue 
of INI1 or inhibition of EZH2, and lymphoma (with EZH2 activating mutations), inhibition of EZH2 leads to 
slowing of tumor growth and apoptosis16–21. Moreover, these data are now supported by early phase clinical stud-
ies where EZH2 inhibitors have shown clinical responses in MRT and lymphoma (unpublished data). Could this 
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strategy be relevant to other sarcomas with INI1/EZH2 alteration? INI1 mutation or loss of expression has been 
described in connective tissue malignancies, including round cell soft-tissue sarcomas (most were a subset of 
tumors resembling extraskeletal myxoid chondrosarcoma with rhabdoid features)22, epithelioid sarcomas23, and 
in poorly differentiated chordoma24. These are all extremely rare histologies (e.g. we estimate there are less than 10 
cases of poorly differentiated chordoma diagnosed in the US per year) and as such, clinical study remains difficult. 
Synovial sarcoma is the third-most common soft tissue malignancy in adolescents and young adults, and accounts 
for up to 10% of all soft tissue sarcomas25. Standard treatment involves multimodality therapy including surgery 
with or without radiation and/or chemotherapy26,27. However, despite this aggressive approach relapse is not 
uncommon and in the metastatic setting synovial sarcoma is universally fatal28,29. Molecularly, synovial sarcoma 
is defined by the chromosomal translocation t(X;18)(p11.2;q11.2), which fuses the SS18 (SYT, a SWI/SNF sub-
unit30,31) gene to either SSX1, SSX2, or rarely SSX428,32. The aberrant fusion protein SS18-SSX fusion is believed 
to derive its oncogenic activity through altered transcription33. Recent models suggest two potential competing 
mechanisms of transforming activity in synovial sarcoma. SS18-SSX displaces wild-type SS18 and INI1 from 
the SWI/SNF complex and this may drive Sox2-mediated proliferation/dedifferentiation31. Alternatively, there is 
evidence that SS18-SSX may directly recruit PRC2 and HDAC to ATF2 targets and thus silence transcription at 
those loci34. Previous studies have implicated the role of the SS18-SSX fusion genes in epigenetic regulation and 
modification of target genes35–38.
In summary evidence suggests that imbalance of SWI/SNF-PRC2/EZH2 can drive oncogenesis in sarcomas. 
In synovial sarcoma the SS18-SSX may drive aberrant gene silencing through either loss of EZH2 inhibition or by 
direct recruitment to polycomb targets. We and others hypothesize that inhibition of EZH2 is a potential clinical 
therapeutic target in synovial sarcoma39–41. This study demonstrates that synovial sarcoma is dependent on EZH2 
for tumor survival and migration.
Results
EZH2 expression in synovial sarcoma human tissue. We sought to confirm that high-level EZH2 
expression is present in human synovial sarcoma samples. The tissue samples were taken from 20 female and 30 
male patients with a median age of 40 years. Semi-quantitative EZH2 expression staining patterns were catego-
rized into 6 groups: 0, no nuclear staining; A, 1+ , < 10% of cells stained positive; B, 2+ , 10% to 25% positive cells; 
C, 3+ , 26% to 50% positive cells; D, 4+ , 51% to 75% positive cells; and E, 5+ , > 75% positive cells. Tumor cell 
staining was nuclear as anticipated. Of the 50 cases, 76% displayed detectable EZH2 expression; the staining inten-
sities were as follows: 1+ = 22%, 2+ = 22%, 3+ = 14%, 4+ = 12% and 5+ = 6% (Supplementary Figure S1A). 
We evaluated the clinical history of the human tumor specimens and found no significant correlation between 
EZH2 expression and tumor tissue type/location, TNM stage, and pathology grade. There were, however, differ-
ences in EZH2 expression between clinical stages; 13 patient specimens were in stage I, 16 in stage II, 20 in stage 
III, and one in stage IV. Patients with stage II and stage III synovial sarcoma had significantly higher EZH2 scores 
(2.188 ± 0.3788, p = 0.0437 and 2.200 ± 0.3524, p = 0.0388, respectively) than stage I patients (1.077 ± 0.3483). 
The individual patient in stage IV did not show any EZH2 staining expression (Supplementary Figure S1B).
Knockdown of EZH2 inhibits synovial sarcoma cell line proliferation. The Aska-SS and Yamato-SS 
cell lines were confirmed to contain the SS18-SSX1 fusion gene variant and the Fuji and SYO-1 cell lines were 
shown to have the SS18-SSX2 fusion gene variant by quantitative RT-PCR (Supplementary Figure S2).
The Fuji and SYO-1 cell lines were transfected with human EZH2 siRNA. After 96 hour cultures siRNA treat-
ment resulted in a knockdown of EZH2 in both cell lines (Fig. 1A), as well as dose-dependent inhibition of pro-
liferation (Fig. 1B). To confirm these findings, lentiviral human EZH2 shRNA was transduced into the Aska-SS, 
Fuji, and SYO-1 synovial sarcoma cell lines. After establishing subcultured stable cell lines through puromycin 
selection, proliferation was assessed by the MTT assay after 96 hours. Knockdown of EZH2 by shRNA inhibited 
proliferation in all cell lines (Aska-SS, Fuji, and SYO-1) while the growth in the control cell lines was unaltered 
(Fig. 1C) similar to siRNA above.
Knockdown of EZH2 suppresses synovial sarcoma cell migration in vitro. EZH2 is the only known 
methyltransferase of H3K27me3;42 thus, to confirm on-target effect, the knockdown of EZH2 expression and its 
trimethylation function were analyzed after 72 hours of treatment. In vitro cell line migration was assessed by a 
semi-quantitative wound-healing recovery assay. EZH2 siRNA was transfected into Yamato-SS, Aska-SS, and 
SYO-1 synovial sarcoma cell lines as described. Following 24 hours of treatment and 48 hours after the wounding 
all cell lines demonstrated inhibition of wound healing with EZH2 siRNA transfection compared with control 
lines.
Western blot results demonstrated a concentration-dependent inhibition of EZH2 expression, and densito-
metric analysis showed decreasing H3K27me3 expression in each of the cell lines, Yamato-SS, SYO-1, and Aska-SS 
(Fig. 2A–C). To rule out apoptotic cell death as the mechanism of suppressed migration, poly(ADP-ribose) pol-
ymerase (PARP) cleavage was assessed. There was no significant difference in PARP cleavage between the differ-
ent concentrations in any cell line at 72 hours, indicating that the inhibition of migration was not related to cell 
viability (Fig. 2A–C).
The Yamato-SS cell line was nearly completed recovered after 48 hours of migration in the control and 
non-specific siRNA transfected cells, covering 3.4 ± 0.027 mm and 3.6 ± 0.15 mm, respectively (Fig. 2D). 
EZH2 siRNA-treated cell line showed inhibition of wound healing at 40 nM (2.6 ± 0.093 mm) and 60 nM 
(1.8 ± 0.31 mm) only with no effect at 20 nM (3.4 ± 0.11 mm).
EZH2 siRNA transfection also suppressed migration in the Aska cell line. EZH2 siRNA transfected cells 
migrated 0.97 ± 0.15 mm and 0.63 ± 0.21 mm, respectively, whereas cells transfected with 20 nM of EZH2 siRNA 
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migrated 0.37 ± 0.00 mm, and greater concentrations of siRNA resulted in no migration and cell detachment 
(Fig. 2E).
Similar migration results were also demonstrated in SYO-1 cells, which travelled 0.50 ± 0.095 mm, 
0.53 ± 0.087 mm, and 0.43 ± 0.10 mm with 20 nM, 40 nM, and 60 nM, respectively, while control and non-specific 
siRNA cells covered 1.3 ± 0.31 mm and 1.1 ± 0.21 mm, respectively (Fig. 2F). Cell migration images are shown 
in Fig. 3.
EPZ005687 specifically targets EZH2 methyltransferase function on H3K27me3. EPZ005687 
is a specific inhibitor of EZH216, and as such H3K27 trimethylation status is a direct marker of PRC2 activ-
ity. Therefore, H3K27me3 protein expression was assessed in synovial sarcoma cell lines after treatment with 
EPZ005687. Aska-SS and SYO-1 cells were treated with increasing concentrations of EPZ005687 and were then 
assessed for H3K27me3 status after 72 hours, apoptosis after 72 hours, proliferation after 14 days and migration 
over 48 hours with 72 hours of constitutive treatment. Western blot and densitometry results demonstrated a 
dose-dependent inhibition of H3K27me3 with EPZ005687 (Fig. 4A,B). The expression of level of EZH2 remained 
constant between treated and indicating inhibition of enzymatic activity without degradation of EZH2 protein.
EPZ005687 inhibits synovial sarcoma cell proliferation and migration. To examine the effect of 
EPZ005687 on synovial sarcoma cell proliferation, Aska-SS, Yamato-SS, Fuji, and SYO-1 cells were treated with 
increasing concentrations of EPZ005687 over 14 days. Inhibition of cell proliferation by EPZ005687 in each cell 
line was determined by the MTT assay. Over 14 days, the non-viable cells appeared to detach from the plate. The 
IC50 of EPZ005687 in Aska-SS was 0.72 μ M, Fuji was 1.5 μ M, SYO-1 was 2.1 μ M, and Yamato-SS was 3.5 μ M 
(Fig. 5A). The chordoma UCH2 cell line and the liposarcoma SW872 cell line do not contain the SS18-SSX 
translocation, and thus, were used as controls. Both cell lines demonstrated limited inhibition of proliferation 
(Supplementary Figure S3).
We further examined the effect of EPZ005687 on synovial sarcoma cell migration over 48 hours with 72 hours 
of constitutive treatment. Concentration gradient ranges were adjusted according to the IC50 determined above. 
Both SYO-1 and Aska-SS cell migration was inhibited with EPZ005687 treatment in a dose-dependent manner 
with an observable threshold below their IC50s (< 1 μ M and < 0.5 μ M, respectively), as compared with untreated 
control cells (Fig. 5B; Supplementary Figure S4). PARP cleavage showed no significant difference between drug 
concentrations, indicating that suppression of migration was not related to cell viability (Fig. 5B).
EPZ005687 in combination with chemotherapy in synovial sarcoma cell lines. To exam-
ine whether inhibition of EZH2 could sensitize synovial sarcoma cells to chemotherapeutic drugs in vitro, the 
Aska-SS and SYO-1 cells lines were treated with increasing concentrations of EPZ005687 and etoposide, topote-
can, or doxorubicin over 14 days, and IC50s were determined by the MTT assay.
There was no significant synergy of EPZ005687 with the chemotherapy drugs in each cell line. In the SYO-1 
cell line, the IC50 of etoposide alone was 0.037 μ M, whereas treatment with EPZ005687 decreased the IC50 to 
0.026 μ M. For topotecan, the IC50 decreased from 0.00065 μ M to 0.00060 μ M when combined with EPZ005687. 
Doxorubicin alone exhibited an IC50 of 0.00089 μ M, and 0.00070 μ M with EPZ005687. The Aska cell line also 
had a similar trend with combination treatments. The IC50 of etoposide alone was 0.066 μ M, and 0.029 μ M in 
Figure 1. Knockdown of EZH2 by synthetic siRNA or lentiviral shRNA inhibits proliferation in synovial 
sarcoma cell lines. (a), Confirmation of EZH2 protein expression knockdown after siRNA transfection in 
SYO-1 and Fuji cell lines by Western blot. (b), Inhibition of cell proliferation after EZH2 siRNA transfection in 
SYO-1 and Fuji cell lines as determined by the MTT assay. (c), Inhibition of cell proliferation after EZH2 shRNA 
transduction in Aska-SS, Fuji, and SYO-1 cell lines as determined by MTT assay. Western blot images were 
cropped to improve the conciseness of the data; samples derive from the same experiment and the blots were 
processed in parallel.
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combination with EPZ005687; topotecan alone was 0.0038 μ M, and 0.0025 μ M with EPZ005687; and doxorubicin 
alone was 0.011 μ M, and 0.0019 μ M together with EPZ005687 (Supplementary Figure S5).
Discussion
Growing evidence has identified supports the SWI/SNF-PRC2/EZH2 axis as a powerful tumor suppressor/onco-
gene pathway. Alterations in SWI/SNF-PRC2/EZH2 are now recognized in a number of tumors and they may 
correlate with aggressive clinical features7,10–14,20,43–50. Preclinical work and ongoing early phase clinical trials sup-
port targeting EZH2 in INI1 or EZH2 altered malignancies. In synovial sarcoma, where SS18-SSX is aberrantly 
expressed, it is hypothesized that EZH2 overactivity, either from loss of SWI/SNF-mediated EZH2 inhibition or 
by direct recruitment of EZH2 to polycomb targets, leads to tumorigenesis.
We first confirmed the presence of EZH2 in human synovial sarcoma samples. There was a higher-level 
expression in stages 2 and 3 in this limited sample. No expression was seen in the stage 4 sample. Due to this 
limited sample size, it would be useful to expand these investigations to a larger scale study. We believe this is an 
inherent limitation of the TMA (e.g. sample bias) as Changchien et al. previously was able to show high levels of 
EZH2 expression in metastatic samples39.
We next explored RNA knockdown and pharmacologic inhibition EZH2 in synovial sarcoma in vitro. We 
demonstrate robust target inhibition with the shRNA and siRNA and in long-term culture growth inhibition and 
cell migration. This appears to be independent of any early apoptotic event as PARP is essentially normal. It is 
important to note, however, that over the course of the long-term cultures some cells would lift off the plate. The 
mechanism of cell death was unknown and technically assays to evaluate apoptosis were not feasible. It is possible 
that these data are consistent with an epigenetic event that requires time to evolve, rather than immediate inhibi-
tion of a kinase oncogene. For example, this would be consistent with the work from Naka et al. where siRNA of 
SS18-SSX appeared to induce differentiation rather than tumor cell line death51.
EPZ005687 is a high-affinity inhibitor for EZH2. Patient trials of the clinical compound Tazemetostat are 
ongoing in Europe and planned for the US in 2016 (NCI NCT02601937 and NCT02601950). In the above work, 
Figure 2. Knockdown of EZH2 by synthetic siRNA restricts migration in synovial sarcoma cell lines  
in vitro. Confirmation of knockdown of EZH2 protein and H3K27me3 expression after EZH2 siRNA 
transfection in Yamato-SS (a), Aska-SS (b), and SYO-1 (c) cell lines as determined by Western blot and 
densitometry. No significant difference in PARP cleavage between the different concentrations indicated that 
the inhibition of migration was not related to cell viability. Suppression of cell migration distance after EZH2 
siRNA transfection in Yamato-SS (d), Aska-SS (e), and SYO-1 (f) cell lines as determined by the wound healing 
assay. Western blot images were cropped to improve the conciseness of the data; samples derive from the same 
experiment and the blots were processed in parallel.
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we treated synovial sarcoma cell lines with EPZ005687. We saw a dose-dependent decrease in H3K27me3 in the 
SYO-1 cell line with variable decrease in the Aska-SS cell line. Of note, despite the limited inhibition on Western 
blotting of H3K27me3 in Aska-SS, there was correlation with increasing dose and inhibition of proliferation in 
the dose-response curve (Fig. 5) confirming on-target inhibition. Indeed, all cell lines had inhibited proliferation 
with EPZ005687. The variable IC50 levels likely reflect a combination of drug-target potency and the kinetics of 
the cell line. For example, SYO-1 grows much more efficiently as compared to Aska-SS and thus the long-term 
Figure 3. Migration images of EZH2 siRNA transfected synovial sarcoma cell lines. Yamato-SS, Aska-SS, 
and SYO-1 cell lines were treated with the specified siRNA concentrations at 0, 8, 24, and 48h time points.
Figure 4. EPZ005687 specifically targets EZH2 methyltransferase function on H3K27me3. H3K27me3 
expression was examined in SYO-1 (a) and Aska-SS (b) cell lines by Western blot and densitometry to confirm 
target specificity of EPZ005687 on EZH2 function and not EZH2 itself. Additionally, there was no significant 
difference in PARP cleavage between the different concentrations in the cell lines. Western blot images were 
cropped to improve the conciseness of the data; samples derive from the same experiment and the blots were 
processed in parallel.
www.nature.com/scientificreports/
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growth curves are more consistent between experiments. For controls, we used liposarcoma and chordoma cell 
lines, not known to have alterations in SWI/SNF members or EZH2. These cell lines were less sensitive to the 
inhibitors (Supplementary Figure S3); however, there was a threshold where both lines displayed some level of 
growth inhibition. It is possible that at high doses EZH2/polycomb is functional or there is some off-target path-
way inhibition.
Our data also demonstrate that EZH2 inhibition by RNA knockdown or pharmacologically inhibits cell 
migration. Further work will be needed to determine the mechanism of this finding. Interestingly, EZH2 has 
been correlated with metastatic pathways in other cancers. EZH2 is thought to regulate invasion by suppressing 
Early Growth Response-1 (EGR1), Ras, NF-κ B, and the Raf-1 kinase. EGR1 expression was found to decrease 
the metastatic potential in a number of cancers, such as non-small cell lung cancer, hepatocarcinoma, and fibro-
sarcoma52–54. EGR1 is repressed by the SS18-SSX fusion protein in synovial sarcoma in that SS18-SSX recruits 
PcG proteins, including EZH2 and Bmi1, to the EGR1 promoter and correlates with H3K27me338. It has also 
been demonstrated that EZH2 activates the Ras and NF-κ B pathways in prostate cancer55. Specifically, the Ras 
GTPase-activating protein (RasGAP) gene DAB2IP is suppressed by EZH2, which in turn activates the metastatic 
pathway progression through Ras and NF-κ B. Furthermore, in breast and prostate cancer EZH2 downregulates 
the Raf-1 kinase inhibitor protein (RKIP) potentially leading to tumor progression and metastasis47.
Recent work has demonstrated synergism of combining EZH2 inhibition with chemotherapy in NSCLC 
and melanoma, particularly topoisomerase inhibitors and platinum56,57. This is attractive as it may expand the 
activity of these agents in clinic. In our work, however, we were unable to demonstrate a significant synergy of 
EPZ005687 in combination with topotecan, etoposide and doxorubicin. Other combinations and novel agents 
may be explored in future work.
Figure 5. EPZ005687 inhibits synovial sarcoma cell proliferation and migration. (a), The IC50 of Aska-SS, 
Fuji, SYO-1, and Yamato-SS treated with EPZ005687 over 14 days as evaluated by the MTT assay. (b), Migration 
distances of SYO-1 and Aska-SS cell lines after 72 h treatment with EPZ005687 as evaluated by the wound 
healing assay. Western blot images were cropped to improve the conciseness of the data; samples derive from the 
same experiment and the blots were processed in parallel.
www.nature.com/scientificreports/
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In summary, the fusion protein SS18-SSX in synovial sarcoma is believed to promote oncogenesis though 
either loss of negative regulation of EZH2/polycomb or by direct recruitment of EZH2/polycomb. In this study 
we show that RNA knockdown or pharmacologic targeting of the EZH2 methyltransferase activity inhibits prolif-
eration and migration across a range of synovial sarcoma cell lines. We believe this work and others provides the 
foundation to explore clinical trials of EZH2 inhibitors in patients with this disease.
Materials and Methods
Cell lines, cell culture, and study agents. The human synovial sarcoma cell lines Aska-SS and Yamato-SS 
which carry the SS18-SSX1 fusion gene were kindly provided by Dr. Kazuyuki Itoh (Osaka Medical Center for 
Cancer and Cardiovascular Diseases, Osaka, Japan)51. The human synovial sarcoma cell line SYO-1 and Fuji 
which carry the SS18-SSX2 fusion gene were generously provided by Dr. Akira Kawai (National Cancer Center 
Hospital, Tokyo, Japan)58 and Dr. Kazuo Nagashima (Hokkaido University School of Medicine, Hokkaido, 
Japan)59, respectively. The human chordoma UCH2 cell line was kindly provided by Dr. Silke Bruderlein 
(University Hospitals of Ulm, Germany)60, and the human liposarcoma SW872 cell line was purchased from the 
American Type Culture Collection (Maryland, USA). The Aska, Yamato, SYO-1, and UCH2 cell lines were incu-
bated in DMEM (Invitrogen, Carlsbad, CA) supplemented with 10% fetal bovine serum, 100 U/mL penicillin, 
and 100 mg/mL streptomycin (Life Technologies, Carlsbad, CA), and the Fuji and SW872 cell lines in RPMI-1640 
(Life Technologies, Grand Island, NY) complete media. All cells were maintained in a humidified incubator con-
taining 5% CO2–95% air atmosphere at 37 °C. Light microscope images were obtained by a Zeiss microscope from 
Carl Zeiss, Inc. (Oberkochen, Germany) with an attached Nikon D40 digital camera (New York, NY).
EPZ005687 (Epizyme Inc., Cambridge, MA) is a specific inhibitor of EZH2 activity16. EPZ005687 was dis-
solved in dimethyl sulfoxide (DMSO) and administered at gradient concentrations to synovial sarcoma cells over 
72 hours for wound healing and western blot analysis. To evaluate drug cytotoxicity, cells were treated for a total 
of 14 days following the manufacturer’s protocol with minor modifications. Briefly, 1.5 × 105 cells were seeded 
in culture medium in a 12-well plate. Fresh media and drug were exchanged on day 4, and cells were reseeded to 
1 × 104 cells per well into 96-well plates in triplicate on day 7 with fresh media and drug. Fresh media and drug 
were again exchanged on day 11, and cell viability was determined by the MTT assay on day 14.
Etoposide (Toposar™ , Teva product #00703565301), topotecan (Hospira product #00409030201), and 
doxorubicin (APP Pharmaceuticals product #63323088305) were obtained from McKesson Medical-Surgical 
(Richmond, VA). Synovial sarcoma cells were treated at gradient concentrations over 14 days alone or in combi-
nation with EPZ005687 for synergism assays, and proliferation was determined by the MTT assay.
Quantitative real-time RT-PCR. To confirm which fusion gene variant in each of the cell lines, total 
RNA was extracted using TRIzol Reagent® (Life Technologies) according to the manufacturer’s protocol. 
RNA samples were quantified using the ultraviolet spectrophotometer at 260 nm (Beckman DU-640, Beckman 
Instruments, Fullerton, CA). Equal amounts of RNA were reverse transcribed using a High-Capacity cDNA 
Reverse Transcription Kit (Applied Biosystems, Foster City, CA). cDNAs were then amplified by real-time PCR 
using TaqMan® gene expression assays (Applied Biosystems) for SS18-SSX1 (Product ID: Hs03024820_ft; probe 
sequence: 5′ -ccagc agaggacgaa aatgattcga agggagtgtc agaagcatct ggcccacaaa acgatgggaa acaactgcac cccccagg-3′ ) 
and SS18-SSX2 (Product ID: Hs03024398_ft; probe sequence: 5′ -ccagc agaggaagga aatgattcgg aggaagtgcc agaag-
catct ggcccacaaa atgatgggaa agagctgtgc cc-3′ ) according to the manufacturer’s protocol. PCR was performed with 
TaqMan® gene expression master mix (Applied Biosystems) using 2 μ L of cDNA in a 20-μ L final reaction volume. 
The amplification cycles were performed by Applied Biosystems StepOnePlus™ System (Applied Biosystems) as 
follows: 50 °C for 2 min, 95 °C for 10 min, followed by 40 cycles of 95 °C for 15 seconds, and finally 60 °C for 1 min-
ute. The housekeeping gene β -actin (Product ID: Hs01060665_g1; probe sequence: 5′ -ggc gtgatggtgg gcatgggtca 
gaaggattcc tatgtgggcg acgaggccca gagcaagaga-3′ ) expression level was used as an internal control to evaluate the 
integrity of each sample.
Synthetic EZH2 siRNA transfection. EZH2 knockdown in human synovial sarcoma cells was performed 
by siRNA transfection. The human EZH2 siRNA (Sigma-Aldrich, SASI_Hs01_00147882) target sequence was 
as follows: sense: CAUCGAAAGAGAAAUGGAAdTdT; antisense: UUCCAUUUCUCUUUCGAUGdTdT. The 
nonspecific siRNA oligonucleotides (Qiaqen, Hilden, Germany) were used as negative controls. Synovial sarcoma 
cells were either cultured on 12-well plates for wound healing and western blot analysis or 96-well plates for cell 
proliferation assays. Various concentrations (0, 20, 40, and 60 nM) of EZH2 siRNA or nonspecific siRNA (40 nM) 
were transfected into cells using Lipofectamine RNAiMax Reagent (Invitrogen, CA, USA) according to the man-
ufacturer’s instructions. After 72 hours, transfected cells were subjected to subsequent analysis.
Lentiviral EZH2 shRNA knockdown. Further evaluation of EZH2 knockdown in synovial sarcoma 
cells was carried out with lentiviral shRNA (Sigma-Aldrich, SHCLNV-NM_004456). The human EZH2 shRNA 
sequence targeted the coding region: 5′ -CCGGTATGATGGTTAACGGTGATCACTCGAGTGATCACCGT 
TAACCATCATATTTTTG-3′ . Briefly, synovial sarcoma cells were seeded (2  ×  103 per well) in a 96-well 
microplate and incubated with EZH2 shRNA lentivirus for 24 hours at 37 °C in a humidified incubator in 
an atmosphere of 5% CO2. Untreated cells were used as blank control, and a lentiviral empty vector and 
lentivirus-based non-specific shRNA were used as negative controls. Each lentiviral construct and control was 
plated in duplicate wells. Hexadimethrine bromide was added to enhance transduction efficacy. Fresh medium 
containing 2 μ g/ml puromycin, which is lethal to most lentivirus-untransduced cells, was exchanged every 3–4 
days until resistant colonies were established. The knockdown effect of EZH2 shRNA was then evaluated by to 
cell proliferation analysis.
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Western blot. Protein lysates of the cells were extracted with 1×  RIPA lysis buffer (Upstate Biotechnology, 
Charlottesville, VA) supplemented with complete protease inhibitor cocktail tablets (Roche Applied Science, IN, USA). 
The protein concentrations were determined by Protein Assay Reagents (Bio-Rad, Hercules, USA). Equal 
amounts of protein were separated by NuPAGE® 4–12% Bis-Tris Gel (Life Technologies), transferred onto nitro-
cellulose membrane (Bio-Rad), and incubated with specific primary antibodies EZH2 (Cell Signaling, Beverly, 
MA, dilution 1:1000), H3K27me3 (Active Motif, Carlsbad, CA, dilution 1:1000), and β -Actin (Sigma-Aldrich, 
St. Louis, MO, dilution 1:2000) at 4 °C overnight. The membranes were further probed with respective secondary 
antibodies (LI-COR Biosciences, Lincoln, NE), and scanned by Odyssey® CLx equipment (LI-COR Biosciences) 
to detect the bands and the density.
Wound healing assay. Cell migration activity was evaluated by wound healing assay. In brief, 2 × 105 cells 
were seeded onto 12-well plates, and treatments were administered. After cells reaching 100% confluence, the 
cells were wounded by scraping of three parallel lines with a 200 μ l tip, and then washed 3 times in serum-free 
medium and incubated in regular medium. Wounds were observed at 0, 8, 24, and 48 h. Three images were taken 
per well at each time point using a 10× objective, and the distance between the two edges of the scratch (wound 
width) was measured at three sites in each image. The cell migration distance was calculated by subtracting the 
wound width at each time point from the wound width at the 0 h time point.
MTT cell proliferation assay and drug cytotoxicity assay. Synovial sarcoma cells were seeded at 
1 × 104 cells per well into 96-well plates, and treatments were administered. After the indicated time periods 
of incubation, 20 μ L of MTT (5 mg/mL, dissolved in PBS, Sigma-Aldrich) was added to each well and the cells 
were cultured for 4 hours at 37 °C. The MTT formazan product was dissolved with acid isopropanol. The absorb-
ance at a wavelength of 490 nm (A490) was measured on a SPECTRAmax Microplate Spectrophotometer from 
Molecular Devices (Sunnyvale, CA).
Tissue Microarray Immunohistochemistry. The expression level of EZH2 was determined follow-
ing the immunohistochemistry protocol (Paraffin) from Cell Signaling Technology (Beverly, MA) as previ-
ously described. The synovial sarcoma TMA was purchased from US Biomax, Inc. (Rockville, MD) containing 
50 cases/100 cores with histopathologic data, including age, sex, tumor tissue type and location, clinical stage, 
TNM grading, and pathology grade. The information of “clinical stages” about this synovial sarcoma TMA is 
available at the vendor’s website (http://www.biomax.us/tissue-arrays/Soft_Tissue/SS1001). A Hematoxylin and 
Eosin stained tissue array slide was made available online by the manufacturer. Briefly, 5-μ m paraffin tissue sec-
tion slides of the TMA were baked for 1 hour at 60 °C, deparaffinized in xylene three times for 10 minutes each, 
and then transferred through graded ethanol (100% and 95%) twice for rehydration, 10 minutes each. After 
heat-induced epitope retrieval, the endogenous peroxidase was quenched by 3% hydrogen peroxide. Following 
protein blocking by normal goat serum for 1 hour at room temperature, the slide was incubated with the EZH2 
primary antibody (dilution 1:50) at 4 °C overnight in a humidified chamber. Subsequently, bound antibody on 
the array was detected by SignalStain® Boost Detection Reagent (Cell Signaling Technology) and SignalStain® 
DAB (Cell Signaling Technology). The nuclei of synovial sarcoma cells were counterstained with hematoxy-
lin QS (Vector Laboratories) to obtain better images. Finally, the section was mounted with VectaMount AQ 
(Vector Laboratories) for long-term preservation. EZH2 expression was evaluated semi-quantitatively according 
to nuclear staining. Staining patterns were categorized on a semi-quantitative scale from 0–5+ as follows: 0, no 
nuclear staining; A, 1+ , <10% of cells stained positive; B, 2+ , 10% to 25% positive cells; C, 3+ , 26% to 50% pos-
itive cells; D, 4+ , 51% to 75% positive cells; and E, 5+ , > 75% positive cells.
Statistical analysis. The data were analyzed using Prism 5.0 software (Graph Pad Software Inc., San Diego, CA), 
and expressed as mean ± SEM. Statistical significance was assessed using independent two-tailed Student t-tests 
for independent data. Differences of p < 0.05 were considered significant for all statistical tests.
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